Tags

Type your tag names separated by a space and hit enter

Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects.
Cytokine 2015; 73(2):265-9C

Abstract

INTRODUCTION

Obesity is associated with low-grade systemic inflammation which is thought to trigger the development of comorbidities such as type 2 diabetes. The soluble receptor for advanced glycation end products (sRAGE) belongs to the innate immune system and has been linked to obesity, recently. The aim of the present study was to examine whether serum sRAGE concentrations are related to the grade of weight loss and improvement of insulin resistance due to a very low calorie diet (VLCD).

METHODS

22 severe obese subjects (Median Body Mass Index (BMI): 44.5kg/m(2)) were included in a dietary intervention study of 6month, consisting of a very low calorie formula diet phase (VLCD: 800kcal/d) for 12 weeks and a following 12 week weight maintenance phase. Fasting glucose, fasting insulin, adiponectin, leptin and sRAGE were determined from sera. Insulin sensitivity was estimated by Homeostasis Model Assessment (HOMA) index and leptin-to-adiponectin-ratio (LAR).

RESULTS

Mean body weight reduction by VLCD accounted to 21.7kg with a significant improvement of insulin resistance. At baseline, sRAGE serum levels were significantly inversely related to BMI (rS=-0.642, p=0.001) and HOMA (rS=-0.419, p=0.041). Of interest, sRAGE serum levels at baseline were significantly lower in study subjects with greater reduction of BMI (p=0.017). In addition, a significantly greater HOMA reduction was observed in subjects with lower sRAGE serum levels at baseline (p=0.006). Finally, correlation analysis revealed, that changes of sRAGE serum levels were significantly correlated to changes of BMI (rS=-0.650, p=0.022) during intervention.

CONCLUSION

Anti-inflammatory sRAGE might be a potential future biomarker to predict weight loss and improvement of insulin resistance by a VLCD whereby lower baseline sRAGE serum levels indicate a better outcome of the dietary intervention.

Authors+Show Affiliations

Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straβe 3, 24105 Kiel, Germany. Electronic address: Imke.Hagen@uksh.de.Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straβe 3, 24105 Kiel, Germany. Electronic address: Dominik.Schulte@uksh.de.Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straβe 3, 24105 Kiel, Germany.Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straβe 3, 24105 Kiel, Germany.Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straβe 3, 24105 Kiel, Germany.Institute of Medical Informatics and Statistics, University of Kiel, Brunswiker Straβe 10, 24105 Kiel, Germany.Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straβe 3, 24105 Kiel, Germany.Department I of Internal Medicine, University of Kiel, Arnold-Heller-Straβe 3, 24105 Kiel, Germany. Electronic address: matthias.laudes@uk-sh.de.

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

25802195

Citation

Hagen, Imke, et al. "Soluble Receptor for Advanced Glycation End Products as a Potential Biomarker to Predict Weight Loss and Improvement of Insulin Sensitivity By a Very Low Calorie Diet of Obese Human Subjects." Cytokine, vol. 73, no. 2, 2015, pp. 265-9.
Hagen I, Schulte DM, Müller N, et al. Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects. Cytokine. 2015;73(2):265-9.
Hagen, I., Schulte, D. M., Müller, N., Martinsen, J., Türk, K., Hedderich, J., ... Laudes, M. (2015). Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects. Cytokine, 73(2), pp. 265-9. doi:10.1016/j.cyto.2015.02.022.
Hagen I, et al. Soluble Receptor for Advanced Glycation End Products as a Potential Biomarker to Predict Weight Loss and Improvement of Insulin Sensitivity By a Very Low Calorie Diet of Obese Human Subjects. Cytokine. 2015;73(2):265-9. PubMed PMID: 25802195.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects. AU - Hagen,Imke, AU - Schulte,Dominik M, AU - Müller,Nike, AU - Martinsen,Jessica, AU - Türk,Kathrin, AU - Hedderich,Jürgen, AU - Schreiber,Stefan, AU - Laudes,Matthias, Y1 - 2015/03/21/ PY - 2014/10/28/received PY - 2015/01/21/revised PY - 2015/02/09/accepted PY - 2015/3/25/entrez PY - 2015/3/25/pubmed PY - 2016/2/9/medline KW - Biomarker KW - Dietary intervention KW - Soluble receptor for advanced glycation end products KW - Very low calorie diet SP - 265 EP - 9 JF - Cytokine JO - Cytokine VL - 73 IS - 2 N2 - INTRODUCTION: Obesity is associated with low-grade systemic inflammation which is thought to trigger the development of comorbidities such as type 2 diabetes. The soluble receptor for advanced glycation end products (sRAGE) belongs to the innate immune system and has been linked to obesity, recently. The aim of the present study was to examine whether serum sRAGE concentrations are related to the grade of weight loss and improvement of insulin resistance due to a very low calorie diet (VLCD). METHODS: 22 severe obese subjects (Median Body Mass Index (BMI): 44.5kg/m(2)) were included in a dietary intervention study of 6month, consisting of a very low calorie formula diet phase (VLCD: 800kcal/d) for 12 weeks and a following 12 week weight maintenance phase. Fasting glucose, fasting insulin, adiponectin, leptin and sRAGE were determined from sera. Insulin sensitivity was estimated by Homeostasis Model Assessment (HOMA) index and leptin-to-adiponectin-ratio (LAR). RESULTS: Mean body weight reduction by VLCD accounted to 21.7kg with a significant improvement of insulin resistance. At baseline, sRAGE serum levels were significantly inversely related to BMI (rS=-0.642, p=0.001) and HOMA (rS=-0.419, p=0.041). Of interest, sRAGE serum levels at baseline were significantly lower in study subjects with greater reduction of BMI (p=0.017). In addition, a significantly greater HOMA reduction was observed in subjects with lower sRAGE serum levels at baseline (p=0.006). Finally, correlation analysis revealed, that changes of sRAGE serum levels were significantly correlated to changes of BMI (rS=-0.650, p=0.022) during intervention. CONCLUSION: Anti-inflammatory sRAGE might be a potential future biomarker to predict weight loss and improvement of insulin resistance by a VLCD whereby lower baseline sRAGE serum levels indicate a better outcome of the dietary intervention. SN - 1096-0023 UR - https://www.unboundmedicine.com/medline/citation/25802195/Soluble_receptor_for_advanced_glycation_end_products_as_a_potential_biomarker_to_predict_weight_loss_and_improvement_of_insulin_sensitivity_by_a_very_low_calorie_diet_of_obese_human_subjects_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1043-4666(15)00100-3 DB - PRIME DP - Unbound Medicine ER -